We examined the antihypertensive efficacy of: 3 mm Hg). In black patients the maximal drop of BP of nifedipine-capsules (70 ± 4/52 ± 4 mm Hg) was greater (1) sublingual-oral single doses of captopril (25 mg) and nifedipine-capsules (10 mg) in 9 + 9 white patients and (P Ͻ 0.02) than that of captopril (48 ± 4/32 ± 3 mm Hg) but similar to that of nifedipine-retard (71 ± 4/49 ± 4 in 9 + 8 black patients with hypertensive crisis; and (2) a single oral dose of the slow-acting preparation of nifedimm Hg). However, in contrast to nifedipine-capsules and captopril, nifedipine-retard produced a slower drop pine-retard (20 mg) in another 10 black patients. Blood pressure (BP) was assessed at 10 min intervals for 6 h in BP. The time of peak drop in BP of both nifedipinecapsules and captopril occurred within the first 2 h after administration. After 6 h, the BP falls induced by these drugs were still significantly lower than the basewhereas with nifedipine-retard it occurred only between 4 and 6 h after administration. Fewer patients reported line placebo values. Hypotensive effect of nifedipinecapsules was established more rapidly than that of capside effects with nifedipine-retard as compared with the other two preparations. We conclude that single doses topril in both white and black patients, and of nifedipineretard in black patients. Considering the area under the of captopril and nifedipine reduces BP for at least 6 h in both white and black patients with hypertensive crisis, curve of BP values during the 6-h treatment, the overall hypotensive effect of nifedipine-capsules was similar to but nifedipine is more potent than captopril in black patients. The slow release form of nifedipine-retard captopril in white patients, but significantly more pronounced than captopril and nifedipine-retard in black effectively and safely lowers BP while achieving a rapid enough effect without the critical rapid falls in BP that patients. In white patients similar maximal drops of BP (mean ± s.e.m.) were obtained with nifedipine-capsules occur with nifedipine-capsules. (71 ± 4/52 ± 4 mm Hg) and with captopril (69 ± 4/50 ±
Introduction
ever, a randomised controlled trial comparing the Acute severe elevation of arterial blood pressure efficacy of these two groups of agents in black and (BP) is a common clinical problem that in most conwhite patients with hypertensive crisis is lacking. ditions requires immediate treatment with antihy-
The reason for this is probably the assumption that pertensive drugs.
1,2 At least theoretically, ideal treatin severe hypertension in black patients the ACE ment would involve non-parenteral administration inhibitors would be less effective than the calcium and a tendency to lower BP gradually towards a antagonists, as it has been suggested to occur in less stable plateau and safety. 3 This may be especially severe forms of hypertension. [10] [11] [12] In the present important in Africa since these circumstances are study we compare the acute hypotensive effectivecommon and conditions for a continuous haemodyness and safety of the sublingual-oral administration namic monitoring of these patients are difficult.
of captopril and of nifedipine-capsules in the treatThus, there is a practical tendency in these situment of hypertensive crisis in black and white ations to avoid intravenous agents and to prefer the patients. Since concern has arisen recently about the use of oral agents, providing their safety and efficacy potential hazard of a rapid reduction of BP, 13, 14 profile is fairly proven. Several studies have shown particularly by short-acting calcium antagonists, 15 that in white, severely hypertensive patients, calwe also evaluated the efficacy of a sustained release cium antagonists and angiotensin-converting preparation of nifedipine in black patients with enzyme (ACE) inhibitors have approximately equal hypertensive crisis.
single sublingual-oral doses of captopril (25 mg) and a t-tube connector. Recordings were accepted only if more than 90% of raw data were valid. From the nifedipine-capsules (10 mg) were evaluated in populations of white and black patients with curve of BP values of each patient we calculated the area under the curve of BP (measured according to hypertensive crisis. Black and Caucasian patients with severe hypertension that were admitted to our the trapezoid rule). institution since 1993 were enrolled in the study after informed consent. Additionally, we also evaluStatistical analysis ated in a third group of 10 black patients with hypertensive crisis the efficacy of a single oral dose of
Results are mean ± s.e.m. We used Student's paired and unpaired t-test with the Bonferroni correction nifedipine-retard (20 mg, sustained release). All patients were submitted to a period of observation for multiple comparisons when necessary, using a specific software developed for analysis of Spaceon placebo for at least 30 min. BP was evaluated every 3 min during this placebo phase. Additional labs 90207 data. 18 Probability of 5% was the level adopted for statistical significance. screening procedures included a comprehensive story and physical examination on admittance, chest radiography, ECG, standard blood chemical tests,
Results
urine tests and optic fundi examination.
Inclusion criteria were: previously untreated The demographic characteristics and baseline data of both black and white populations that were patients or known hypertensive patients without any therapy for at least 2 weeks, aged 20-60 years, included in the study are summarised in Table 1 . There were no significant differences between the men and non-pregnant women of non-childbearing potential with an average supine diastolic BP (DBP), treatment groups within each population, or between the treatment groups of each population for and with an average supine diastolic BP Ͼ120 mm Hg as a mean of the last three automatic readage, gender, of plasma creatinine values and of BP values (Table 2 ) after placebo period. In all patients ings over the last 10 min of the placebo period. Excluding criteria were: aortic dissection; recent the dissolution under the tongue and the swallowing of either captopril tablet or nifedipine-capsule myocardial infarction or cerebrovascular accident; hypertensive encephalopathy; known renal artery always took less than 5 min. The tablets of nifedipine-retard were swallowed immediately after stenosis or renovascular hypertension; acute or chronic heart failure and a serum creatinine value administration. Heart rate did not significantly change with any of more than twice the upper limit of normal.
After the placebo phase, eligible patients within of the drugs studied. In white patients, captopril produced a fall in BP that on average reached sigeach black or white group were randomly assigned to either captopril or nifedipine-capsule treatment.
nificance for systolic BP (SBP) at 20 min (from 224 ± 7 to 210 ± 6 mm Hg, P Ͻ 0.05), and for DBP at 30 Captopril (25 mg) or nifedipine-capsules (10 mg) were chewed and saliva swallowed after 5 min.
min (from 139 ± 3 to 129 ± 3 mm Hg, P Ͻ 0.03) after drug administration, whereas nifedipine-capsules Although still controversial 16, 17 this method gives a rapid rise in blood levels of nifedipine and, in the produced a fall in BP that on average reached significance for SBP at 10 min (from 222 ± 5 to 196 ± case of captopril, should correspond to oral administration which can reduce BP within 30 min. 7 Black 6 mm Hg, P Ͻ 0.02) and for DBP at 10 min (from 141 ± 2 to 124 ± 3 mm Hg, P Ͻ 0.01) after drug patients of a third group swallowed a tablet of nifedipine-retard (20 mg, sustained release). At the time administration.
In black patients, captopril produced a fall in BP of drug administration BP monitoring was started using a Spacelabs 90207 which was programmed to that on average reached significance for SBP at 20 min (from 223 ± 7 to 207 ± 5 mm Hg, P Ͻ 0.05) and record BP and heart rate every 10 min during the following 6 h of duration of the trial.
for DBP at 30 min (from 140 ± 5 to 134 ± 3 mm Hg, P Ͻ 0.05) after drug administration, whereas nifedipine-capsules produced a fall in BP that on average BP measurement reached significance for SBP at 20 min (from 221 ± 7 to 197 ± 6 mm Hg, P Ͻ 0.02) and for DBP at 10 BP was evaluated every 3 min during each 30-min placebo phase with a Dinamap (Critikon 1846 SX min (from 151 ± 3 to 132 ± 3 mm Hg, P Ͻ 0.01) after administration. With nifedipine-retard, the fall in vital signs monitor) to avoid observer bias. The machine was calibrated against a mercury sphygmo-BP reached significance for SBP at 20 min (from 228 ± 6 to 203 ± 6 mm Hg, P Ͻ 0.05) and for DBP at manometer before use in each patient with a maximum acceptable difference of ±5 mm Hg. At the 30 min (from 151 ± 3 to 139 ± 3 mm Hg, P Ͻ 0.02) after administration. moment of administration of captopril, nifedipinecapsules or nifedipine-retard continuous BP was Table 2 shows for white and black populations and for all treatments the average BP values at baserecorded using an automated non-invasive device (SpaceLabs: Model 90207, SpaceLabs, Redmont, line, at the moment of the maximal effect and at 2 and 6 h after drug administration, as well as the WA, USA). For each patient BP readings were taken at 10-min intervals thereafter for the next 6 h with values of the area under the curves of BP values calculated from the time of administration up to 2 and patients supine. When the instrument was fitted, automatic BP had to be within 5 mm Hg of three 6 h after. In white patients captopril and nifedipinecapsules produced similar maximal drops of SBP simultaneous readings obtained on the same arm with a standard mercury sphygmomanometer using (on average 31% for nifedipine and 30% for captop- ril, vs placebo values) and of DBP (on average 25% tration (for both SBP and DBP), and for captopril by 120 min (range 70 to 180) after administration (for for nifedipine and 23% for captopril vs placebo values). The magnitude of the mean peak drop in both SBP and DBP). For nifedipine-retard peak effect occurred later, ie, by 270 min (range 260 to SBP/DBP of nifedipine-capsules (71 ± 4/52 ± 4 mm Hg) was similar to that of captopril (69 ± 4/50 330) after administration (for both SBP and DBP). Two hours after administration nifedipine-capsules ± 3 mm Hg). On average the peak effect occurred for nifedipine-capsules by 60 min (range 40 to 90) after and captopril produced a fall in BP that was roughly similar to their peak effect, whereas at that time, the drug administration (for both SBP and DBP), and for captopril by 100 min (range 80 to 160) after adminisfall in BP induced by nifedipine-retard was only 70% of its maximal effect. Also the area under the tration (for both SBP and DBP).
In black patients, nifedipine-capsules vs placebo curve of the BP values during the first 2 h of treatment was significantly higher with nifedipine-capproduced a maximal drop of SBP (on average 31%) and of DBP (on average 31%) that were similar to sules than with nifedipine-retard. At 6 h after administration, the BP falls induced by nifedipinethe maximal drop of SBP (on average 31%) and of DBP (on average 32%) induced by nifedipine-retard, capsules, captopril and nifedipine-retard in both populations were still significantly lower than the but higher (Table 2 ) than the maximal drop induced by captopril on SBP (on average 22%) and on DBP pretreatment placebo values. The BP falls induced by nifedipine-capsules and by captopril at 6 h were (on average 18%). The magnitude of the mean peak drop in SBP/DBP of nifedipine-capsules (70 ± 4/52 similar in white patients (on average 19% for nifedipine-capsules and 20% for captopril for SBP, and ± 3 mm Hg) was greater (P Ͻ 0.02) than that of captopril (48 ± 4/32 ± 3 mm Hg) but not different from 14% for nifedipine-capsules and 17% for captopril for DBP) as well as in black patients (on average that of nifedipine-retard (71 ± 4/49 ± 4 mm Hg). On average the peak effect occurred for nifedipine-cap-18% for nifedipine-capsules and 15% for captopril for SBP, and 19% for nifedipine-capsules and 14% sules by 90 min (range 70 to 130) after adminis-for captopril for DBP). BP falls at 6 h induced by arations and after nifedipine-retard. In white patients, captopril provided a slower drop in BP nifedipine-retard in black patients were on average 30% for SBP, and 29% for DBP.
than nifedipine-capsules. After 90 min from administration the BP fall was almost identical with both In white patients, for nifedipine-capsules and captopril, the values of the area under the curves of the drugs. In black patients captopril produced a slower drop in BP than nifedipine-capsules. Also, captopril SBP and DBP values measured during the first 2 and 6 h after administration were not statistically differhypotensive effect was kept along the first 6 h after administration in higher BP levels than nifedipineent. In black patients, for the first 2 h after drug administration, the values of the area under the capsules. From 60 min after nifedipine-capsules and captopril the hypotensive effect of both drugs were curves of SBP and DBP were significantly higher for captopril and for nifedipine-retard than for treatmaintained relatively stable for the next 5 h. In comparison with nifedipine-capsules, with nifedipinement with nifedipine-capsules. For the 6 h after administration the areas under the curves of the SBP retard the BP fell much more slowly and continuously up to 6 h after administration and was mainand DBP were higher for captopril than for nifedipine-capsules and nifedipine-retard, and higher for tained for the first 4 h on a higher level than the effect of nifedipine-capsules. nifedipine-retard than for nifedipine-capsules. Figure 1a and 1b shows the evolution of mean No significant side effects were observed in both populations with both drugs. Headache was more values of SBP and DPB measured at 10 min intervals that were observed before and up to 6 h after the frequently reported after nifedipine both in white (four patients) and in black patients (three patients), administration of captopril or nifedipine-capsules in white and black patients, after these two prepwhereas bad taste was reported more frequently with captopril (by three white and by two black patients). Two patients on nifedipine-retard reported a mild transitory flush.
Discussion
In black populations, hypertension occurs with higher frequency than in non-black populations and is associated with an accelerated target-organ damage. 1,19-22 Also, black patients with hypertensive crisis may present a worse prognosis as compared with white patients. 23 Recently, evidence has been accumulated suggesting that black hypertensive patients respond less effectively to antihypertensive drugs like beta-blockers or angiotensin-converting enzyme inhibitors than do non-black hypertensive patients, 11, 24, 25 and that diuretics and calcium antagonists may be particularly more effective in black hypertensive patients than antihypertensive agents. 11, 24, 25 Moreover, it has been shown in black hypertensive patients that chronic nifedipine monotherapy was more efficient in controlling BP than captopril monotherapy. 10 The present study was a randomised placebo-controlled parallel study aimed to compare the effect of nifedipine-capsules and captopril in black or nonblack populations with hypertensive crisis. Over the last few years several studies have demonstrated the acute efficacy of either nifedipine-capsules or captopril administered sublingually and orally in the urgent treatment of hypertension. [4] [5] [6] [7] [8] [9] [26] [27] [28] [29] To our knowledge only a few placebo-controlled studies have compared the efficacy of both drugs as an acute treatment of hypertension.
Our present study shows that in white patients with hypertensive crisis, single doses of nifedipinecapsules and captopril produced a similar drop in throughout the period of 6 h after administration.
Thus, we may conclude that similarly to what has preparations that may decrease BP more gradually and slowly in patients with hypertensive urgencies. been described for chronic therapy with captopril
In that context we studied in another group of and nifedipine in black hypertensive patients, [10] [11] [12] black patients with hypertensive urgencies the effithe acute antihypertensive efficacy of nifedipinecacy of a single oral administration of a slow release capsules in black patients is also greater than captopreparation of nifedipine. In these patients, a single pril. This greater responsiveness of hypertensive oral dose of nifedipine-retard slowly reduced BP up black subjects to nifedipine than to captopril could to 6 h after administration in a more gradual way if be related to a more salt-sensitive status, to a greater compared with either nifedipine-capsules or captotendency towards expanded plasma volume and to pril. The area under the curve of BP values during a lower plasma renin activity. Whatever may cause the first 2 h of nifedipine-retard was higher than that a lower efficacy of captopril in black patients as of nifedipine-capsules. Also, while the peak effect compared with non-black hypertensive patients, our of nifedipine-capsules and captopril occurred durresults are in agreement to the previous finding that ing the first 2 h of treatment, the peak effect of nifedgreater doses of the ACE inhibitor trandolapril are ipine-retard occurred clearly later, always after 4 h needed for the chronic control of BP in black comof treatment. These data show that nifedipine-retard pared with white hypertensive patients. 12 Although produce a slower and less hypotensive effect within in black patients nifedipine-capsules were found to the first hours of treatment as compared with the be more potent than captopril for the decrease of BP, other two preparations. Since in hypertensive crisis this does not allow us to conclude that nifedipinethe aim is to achieve a BP control within the next capsules is better than captopril for the treatment of 12-24 h, it seems that our data support a rapid hypertensive crisis in blacks. In fact the level to enough BP-reducing effect of nifedipine-retard for which BP should be reduced in patients with hyperhypertensive crisis that is achieved more gradually tensive crisis is still controversial. 30 When the therand within a safer profile. apy-induced BP fall occurs, the adaptation of
In conclusion, the present study shows that in cerebral blood flow works within the limits of the both white and black patients with hypertensive autoregulatory curve 31 and some patients may be crisis, single doses of captopril and nifedipine-capexposed to the hazards of a fall in cerebral blood sules produce an over-rapid and profound acute flow when systemic BP is lowered abruptly by more drop in BP to an extent that may potentially increase than about 25%.
the risk for the development of a critical reduction As reported by other authors 4, 7, 8 in the present in cerebral blood flow. Both drugs look equipotenstudy the hypotensive effect of nifedipine-capsules tial in white patients whereas nifedipine-capsules was obtained earlier than captopril in both white appears to be much more potent than captopril in and black patients. In our study, both captopril and black patients, which reinforces the concept that nifedipine-capsules produced a profound acute black hypertensive patients show a lower respondrop in BP although the BP fall induced by captopril siveness to ACE inhibitors compared with non-black in black patients was significantly less than the hypertensive patients. A single dose of nifedipineeffect of nifedipine-capsules; from this point of view retard produced a more gradual although rapid captopril could be considered safer than nifedipineenough BP-reducing effect for hypertensive capsules for the treatment of hypertensive crisis in urgencies with a less potential risk of reducing cerblack patients. Interestingly, we were unable to ebral flow. Thus, for patients with hypertensive detect in both white and black populations any urgencies that are suitable for treatment with nifedisymptoms of cerebral hypoperfusion despite the pine, the nifedipine-retard formulation may be a tremendous fall of BP that was found at the time of preferable choice. peak effects. One factor that may be responsible for the absence of symptoms of cerebral ischaemia with Moreover, although captopril has been widely used in the present study or, alternatively, to prefer other
